Dermapharm Holding (Germany) Performance
| DMP Stock | 37.80 0.20 0.53% |
Dermapharm Holding has a performance score of 5 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0178, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Dermapharm Holding are expected to decrease at a much lower rate. During the bear market, Dermapharm Holding is likely to outperform the market. Dermapharm Holding right now shows a risk of 2.01%. Please confirm Dermapharm Holding treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to decide if Dermapharm Holding will be following its price patterns.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Dermapharm Holding SE are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Dermapharm Holding may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
| Begin Period Cash Flow | 120.3 M | |
| Total Cashflows From Investing Activities | -129.3 M |
Dermapharm |
Dermapharm Holding Relative Risk vs. Return Landscape
If you would invest 3,500 in Dermapharm Holding SE on September 27, 2024 and sell it today you would earn a total of 280.00 from holding Dermapharm Holding SE or generate 8.0% return on investment over 90 days. Dermapharm Holding SE is generating 0.1419% of daily returns and assumes 2.0148% volatility on return distribution over the 90 days horizon. Simply put, 17% of stocks are less volatile than Dermapharm, and 98% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Dermapharm Holding Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dermapharm Holding's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dermapharm Holding SE, and traders can use it to determine the average amount a Dermapharm Holding's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0704
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | DMP | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.01 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Dermapharm Holding is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dermapharm Holding by adding it to a well-diversified portfolio.
Dermapharm Holding Fundamentals Growth
Dermapharm Stock prices reflect investors' perceptions of the future prospects and financial health of Dermapharm Holding, and Dermapharm Holding fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dermapharm Stock performance.
| Return On Equity | 0.38 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 2.68 B | |||
| Shares Outstanding | 53.84 M | |||
| Price To Book | 4.69 X | |||
| Price To Sales | 2.04 X | |||
| Revenue | 942.91 M | |||
| EBITDA | 357.65 M | |||
| Cash And Equivalents | 161.38 M | |||
| Total Debt | 574.72 M | |||
| Book Value Per Share | 9.36 X | |||
| Cash Flow From Operations | 250.37 M | |||
| Earnings Per Share | 3.32 X | |||
| Total Asset | 1.41 B | |||
About Dermapharm Holding Performance
Assessing Dermapharm Holding's fundamental ratios provides investors with valuable insights into Dermapharm Holding's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Dermapharm Holding is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Dermapharm Holding performance evaluation
Checking the ongoing alerts about Dermapharm Holding for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dermapharm Holding help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 65.0% of the company shares are held by company insiders |
- Analyzing Dermapharm Holding's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dermapharm Holding's stock is overvalued or undervalued compared to its peers.
- Examining Dermapharm Holding's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dermapharm Holding's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dermapharm Holding's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dermapharm Holding's stock. These opinions can provide insight into Dermapharm Holding's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Dermapharm Stock Analysis
When running Dermapharm Holding's price analysis, check to measure Dermapharm Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermapharm Holding is operating at the current time. Most of Dermapharm Holding's value examination focuses on studying past and present price action to predict the probability of Dermapharm Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermapharm Holding's price. Additionally, you may evaluate how the addition of Dermapharm Holding to your portfolios can decrease your overall portfolio volatility.